Jiangbo Pharmaceuticals — Investor Presentation (May 2010)
27 slides from Jiangbo Pharmaceuticals's investor presentation, May 20, 2010

Slide 1: Jiangbo Pharmaceuticals, Inc. Corporate Presentation
Exhibit 99.2 yo Wigs Jiangbo Pharmaceuticals, Inc. Corporate Presentation May 2010

Slide 2: Safe Harbor Statement
Safe Harbor Statement ee ———S This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual r

Slide 3: Reasons to Invest
Reasons to Invest ) Attractive valuation and strong financial position Extensive sales network Government support for extending healthcare benefits Growth opportunities through acquisitions of pharmaceutical companies or new drugs

Slide 4: Equity Snapshot
Equity Snapshot Ss Jiangbo researches, develops, produces, markets and sells Western and Chinese Traditional Chinese Medicines (TCMs) in the form of tablets, time-release capsules, granules, syrups and electuaries (sticky syrup) Stock Symbol: JGBO.OB Price (05/13/10): $8.25 Market Cap: $95.0 Million

Slide 5: Investment Highlights
Investment Highlights Pr ee 2. e Portfolio of sophisticated branded drugs « 4 Western chemical drugs and 13 Traditional Chinese Medicines « 17 approved TCM's waiting for launch « Jiangbo branded products are popular among consumers e Extensive distribution with scalable growth « Using 26 independent

Slide 6: Market Growth Drivers
Market Growth Drivers aaBn ————EEEE * China, currently the world’s sixth-largest pharmaceutical market, will account for 21% of global sales growth in the pharmaceutical industry through 2013, with projected average annual growth of 40% through 2011. * * By 2011, China should become the third-bigges

Slide 7: Company History
Company History S fm + 2009: December — Obtained renewal of GMP certificate for its main manufacturing factory + 2009: April — Company name changed to Jiangbo Pharmaceuticals, Inc. (OTCBB: JGBO) + 2009: February — Completed acquisition of Hongrui Pharmaceuticals’ physical assets and the rights to ma

Slide 8: Modern Facilities
Modern Facilities Teas Operations in Laiyang City, Yantai, Shandong Province, PRC 10,900 square meters of production, office, and storage space 1,535 employees - including 425 production crew, 110 administrators, 440 full-time salespeople and 560 part-time salespeople | Annual production capacity in

Slide 9: Accredited Production
Accredited Production SE « Has certificates of Good Manufacturing Practices for Pharmaceutical Products (an international standard) from the Shandong State Drug Administration A Ae at HA A UE SEA BL AWRGMPIER Sein emia

Slide 10: Production Process
Production Process 4

Slide 11: Well Established Brand Name
Well Established Brand Name ) RHSRRER Clarithromycin sustained- _Itopride Hydrochloride Baobaole chewable Radix Isatidis release tablet granules tablet Dispersible Tablets - Kang Gu Sui Yan Pian (an Laiyang Pear Cough Syrup osteomyelitis treatment tablet) ae Bec Yi Mu Cao Gao (a motherwort herb elec

Slide 12: Product Portfolio
po) Product Portfolio ame ~~ ie ~ Clarithromycin 39.9% Infections such as pneumonia, Top 2 manufacturer in bronchitis and infections of the ears, sustained-released a China sinuses, skin, and throat tablets Itopride Hydrochloride 26.2% Gastro-intestinal system related Top 8 manufacturer in granules

Slide 13: Hongrui TCM Products
Hongrui TCM Products en In early 2009, Jiangbo purchased the rights to manufacture and distribute 22 TCMs 14 products selected for production during the first phase Laiyang Pear Lalyang Pear syrup and pulps to contro! coughs 1) Lalyang Pear Cough Syrup series arising from various factors Osteomyelit

Slide 14: R&D and Product Pipeline
R&D and Product Pipeline Jiangbo has built close relationships with several well known Chinese R&D institutions + The Institute of Microbiology, Chinese Academy of Sciences + Pharmaceutical institute of Shandong University + Shandong Chinese Traditional Medicine Technical School Collaboration with R

Slide 15: Extensive Distribution Network / Marketing and Advertising
Extensive Distribution Network / © Marketing and Adverti ng LH - Cover all of China except for Ningxia - Sell to hospitals and pharmacies mostly through 26 first tier distributors . Internal sales team of 1000 persons - Organize cooperative promotional activities with distributors . Advertise Over T

Slide 16: Management Team
Management Team ems lm —=E Wubo Cao, Chief Executive Officer and Chairman Chairman and General Manager of Laiyang Jiangbo Pharmaceutical Co. Ltd. since 2003 Experienced in founding and managing drug manufacturing companies Has over 20 years of work experience in Chinese pharmaceutical industry Elsa

Slide 17: Business Strategy
Business Strategy S Continue to source and develop sophisticated drugs that meet certification and patent standards and have long product life spans Leverage the distribution network to deepen and expand distribution to existing markets and underserved rural markets in coordination with government p

Slide 18: Financial Highlights
S Wigs] Jiangbo Pharmaceuticals, Inc. Financial Highlights

Slide 19: Strong Revenue Growth
Strong rl Line Growth.-- S i CAGR=24.1% 80 74 a 96 -98 762 40 20 0 FY2007 Fy2008 Fy2009 FY2010E (Fiscal Year Ends June 20) 2010 estimated revenue reflects new company strategy beginning in January 2009 to charge lower unit prices to its 26 independent distributors to shift marketing expenses to dist

Slide 20: Financial Growth from Key Drugs
Financial Growth from Key Drugs S eee Revenue Breakdown by Drug FY2007 FY2008 FY2009 9 mo FY2010" 1 Others 1 Kopride Hydrochloride granules 0 Carithromycin sustained-release tablets 1 Baobaole chewable tablets 1 Radix Isatidis Dispersible Tablets, * For the nine months ended March 31, 2010 me

Slide 21: Gross Profit and Gross Margin
FY2007 FY2008 FY2009 FY2010E Gi Gross Profit —@Gross Margin 2009 revenue reflects new company strategy beginning in January 2009 to charge lower unit prices to its 28 independent distributors to shift marketing expenses to distributors. 20108 is estimated based on reported gross margin for the nine

Slide 22: Income From Operations
Income From Operations== a we 607 re + 50% 5 42.4% : = + 40% ¢ 32.4% 40 42-44 30% 24.0% 30+ 32.2 20% 20+ ‘| | ' Oo 0% FY2007 FY2008 FY200E [a Income From Operations —@— Operating Margin 22

Slide 23: Net Income
Net Income FY2007 FY2008 FY2009 9 mo FY2010* a Net Income Net Margin * For the nine months ended March 31, 2010 23

Slide 24: Summary Income Statement ($ in millions)
($ in millions) For Twelve Months Ended For Nine Months Period June 30 Ended March 31 “2007, =—=s—=i«200s—tti« 2009 “20092010 Total Sales Revenue 76.2 99.5 117.4 86.2 68.1 Gross Margin 72.2% 114% 76.2% TIA% 73.7% SGA Expenses 25.6 41.6 35.3 314 13.4 Operating Margin 24.0% 32.4% 42.4% 37.2% 49.2% Net

Slide 25: Balance Sheet ($ in thousands)
t ($ in thousands) Working Capital Cash Accounts Receivable, Net of Allowance Inventories Total Current Assets Total Assets Total Current Liabilities Total Liabilities Retained Earnings Total Shareholders' Equity June 30, 2008 73,156 48,196 24,312 3,906 89,534 114,395 16,378 18,878 39,008 95,516 Jun

Slide 26: Investment Summary
Investment Summary S Attractive valuation and strong financial position Extensive sales network Government support for extending healthcare benefits Growth opportunities through acquisitions of pharmaceutical companies or new drugs

Slide 27: Contacts
Contacts oO) Se Jiangbo Pharmaceuticals, Inc. Ms Elsa Sung, CFO Phone: (954) 903-9378 ex 2 Email: elsasung@jiangbo.com http:/Awww.jiangbopharma.com/ CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com http:/Awww.ccgir.com/ 27
Source: SEC EDGAR · 8-K filed May 20, 2010